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a  b  s  t  r  a  c  t
Dogs  naturally  infected  with  Leishmania  Infantum  (=L.  chagasi)  were  treated  with  miltefos-
ine using  different  therapeutic  regimens.  The  animals  were  evaluated  for clinical  evolution,
biochemical  parameters,  parasite  load  (by  real-time  PCR),  cytokine  levels  and  humoral
response.  After  treatment  and  during  the  following  24  months,  there  was  progressive  clin-
ical improvement  and  complete  recovery  in 50%  (7/14)  of the  treated  animals.  There  was
a decrease  in  the smear  positivity  of  the  bone  marrow  after  treatment,  and  there  was also
a gradual  and  constant  decrease  in positive  cultures  at the  end  of  the  follow-up  period.
However,  the  PCR  detection  of parasite  DNA  remained  positive.  In general,  all animals  pre-
sented a signiﬁcant  increase  in  parasite  load  6  months  after  treatment.  The  IFN-  levels in
all the  groups  tended  to  increase  during  follow-up  period,  regardless  of  the  miltefosine  dose
administered. The  IL-4  and  IL-10 levels  of  the  animals  tended  to decrease  during  follow-up,
except after  300  days  when  only  IL-10  increased.  The  serum  antibodies  identiﬁed  antigens
that ranged  from  116  kDa  to less  than  29  kDa  in  the Western  blot  assay.  Furthermore,  300
days after  treatment,  qualitative  and quantitative  differences  in  the antigen  proﬁles  were
observed. Antigens  of 97 and 46  kDa  were  the  most  intensely  recognized.  Higher  levels  of
antigen-speciﬁc  Leishmania  IgG were  detected  before  and  300  days  after  treatment  in all
groups. Taking  together,  the  improvement  in  the clinical  symptoms  was  not  followed  by
parasitological  clearance,  suggesting  that  treatment  with  miltefosine  is  not  recommended,
especially  in endemic  areas  like Brazil,  where  children  are  the  major  victims  and  dogs  are
involved in  the  maintenance  of the  parasite  cycle.. IntroductionLeishmaniasis infects approximately 12 million indi-
iduals in 88 countries, and 350 million people are at
isk  of contracting the infection (http://www.who.int/en/).
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Depending on the species of Leishmania and the immune
response of the host, there are several clinical manifesta-
tions of the disease: cutaneous, mucocutaneous, diffuse,
and  visceral. Visceral leishmaniasis (VL), a more severe dis-
ease,  is considered to be an anthroponosis in India and
Central Africa and a zoonosis in the Mediterranean and
Open access under the Elsevier OA license.the  Americas. The zoonotic VL caused by L. infantum (also
known  as L. chagasi) accounts for 20% of the global human
visceral leishmaniasis (100,000 cases per year), and its inci-
dence  is increasing in urban and peri-urban areas of the
ary Para84 H.M. Andrade et al. / Veterin
tropics (Dye, 1996). The domestic dog is considered to be
the  primary reservoir and plays a central role in transmit-
ting the parasite to humans and sand ﬂies.
Brazil has the highest incidence of zoonotic VL in the
world, with about 3000 new cases per year. Moreover, the
number  of areas with incidences that favor a widespread
epidemic, which could affect young people or individuals
with co-morbidities and cause a high number of deaths,
is  increasing. The mortality rate of VL has increased from
3.6%  in 1994 to 6.7% in 2003, which represents an inﬂation
of  85% (Ministério da Saúde, 2006). The control measures
adopted include the diagnosis of canine and human cases,
which  is followed by the treatment of infected humans
and euthanasia of infected dogs. The euthanasia of animals
is  a controversial measure, and alternatives for treatment
are highly desirable. There is, however, a lack of obvious
alternatives for the treatment of human and canine VL.
Miltefosine has just become available in India for the
treatment of human VL. This drug is an alkyphospholipid
that was originally developed as an oral antineoplastic
agent (Sundar et al., 1998). Miltefosine is a simple, very sta-
ble,  relatively safe, and highly efﬁcient molecule. Currently
in  clinical trials, it has become the ﬁrst oral drug available
for  the treatment of human visceral and cutaneous leish-
maniasis. Miltefosine is toxic for Leishmania parasites, and
it  enhances both T cell and macrophage activation and the
production of microbicidal reactive nitrogen and oxygen
intermediates (Soto et al., 2006).
Few studies have been conducted using miltefosine
for the treatment of Canine Visceral Leishmaniasis (CVL).
Recently, it was shown that treatment with miltefosine
alone reduced Leishmania replication, and the parasite was
eradicated from the blood, although it was not removed
from the lymph nodes (Manna et al., 2008a). This phe-
nomenon may  be a potential reason for the recurrence of
the  disease. Furthermore, clinical information on the efﬁ-
cacy  and action of miltefosine for the treatment of canine
leishmaniasis is limited.
The  objective of the current study was to treat dogs
naturally infected with L. Infantum in Brazil endemic area
using  different protocols. The animals were evaluated for
clinical  evolution, biochemistry, parasite load (by real-time
PCR),  cytokine levels and humoral response. To the authors’
knowledge, this is the most complete study concerning the
treatment  of CVL with miltefosine in Americas.
2. Materials and methods
2.1.  Animals
The study protocol was approved by the Research Ethics
committee of the Federal University of Piauí.
Fourteen mongrel animals (Canis familiaris) of unknown
ages were diagnosed by seroepidemiology for CVL, which
was  performed during the control program by the Zoonoses
Control Center of the municipality of Teresina, Piauí, Brazil.
The  animals were diagnosed with an indirect immunoﬂu-
orescence assay (IFA). The seropositive dogs were donated
to  the kennel of the Federal University of Piauí to be used
in  the experiments.sitology 181 (2011) 83– 90
The  diagnosis of Leishmania infection was  conﬁrmed by
serological tests (IFA—cut off 1:80), conventional PCR and
the  detection of amastigotes in smears of bone marrow.
Before beginning the treatment schedule, the dogs were
treated for parasites (endo and exo) and clinically inspected
for  other possible co-infections (Babesiosis, Erlichiosis and
dermatosis). They were kept in a kennel protected by an
anti-sand ﬂy screen with water and food “ad libitum” dur-
ing  the treatment and throughout the follow-up period.
Three  different miltefosine treatment schedules were
administered as described below:
Group 1 (n = 5): 100 mg  miltefosine/animal, administered
daily over a period of 28 days.
Group 2 (n = 5): 200 mg  miltefosine/animal, administered
daily for 28 days.
Group  3 (n = 4): 100 mg  miltefosine/animal, administered
daily for 45 days.
2.2. Clinical evaluation
Before,  immediately after, and at 3-month intervals
over a period of 2 years after treatment, the animals
were evaluated for the presence of clinical symptoms of
VL,  such as dermatitis, skin ulceration, alopecia, ocular
lesions, lymphadenopathy, weight loss, epistaxis, diar-
rhoea,  and onychogryphosis. For each assessment, blood
samples were collected for laboratory analysis. At the end
of  these analyses, all animals were sacriﬁced according
to resolution no. 714 of the Federal Council of Veterinary
Medicine (CFMV) and submitted to necropsy. A spleen
fragment was collected for Leishmania isolation, and the
parasite  load was determined by q-PCR (quantitative PCR
using  real time-PCR).
2.3.  Biochemical evaluation
The  alanine aminotransferase (ALAT), aspartate amino-
transferase (ASAT), total protein, albumin, globulin,
direct/indirect bilirubin, urea, and creatinine levels were
determined in blood samples collected from each exper-
imental group at the intervals mentioned above. An
automated biochemical analyzer (Ciba® Express 550) and
the  compatible, commercial reagents (Labtest®) were
employed. The samples were processed by the kinetic
enzymatic method according to the manufacturer’s recom-
mendations. All of the tests were performed in the Clinical
Pathology Laboratory of the Veterinary Hospital of the Fed-
eral  University of Piauí.
2.4.  Parasitological evaluation
The presence of Leishmania was investigated in bone
marrow samples obtained by sternal puncture from ani-
mals  under sedation. Giemsa smears were obtained from
these  samples and evaluated by microscopy. An aliquot of
the  bone marrow aspirate was transferred to the NNN-
LIT  culture medium, which was maintained at 25 ◦C and
examined weekly for 30 days.
The parasite loads in the bone marrow and spleen sam-
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xtracted with phenol–chloroform, as described by Silva
t  al. (2010). To minimize errors in the quantiﬁcation of
he  parasite load due to differences in the concentration of
otal  DNA, all of the samples were normalized to the low-
st  concentration of DNA obtained from a smear, which
as  20 ng/ml, while the spleen samples were adjusted to
00  ng/mL.
L.  infantum promastigotes culture in monophasic
edium was used to construct standard curves of DNA
ass  vs. number of parasites. The cultured promastigotes
ere counted 10 times in a Neubauer hemocytometer and
sed  to calculate the mean count, and the culture was seri-
lly  diluted to produce samples that contained 1, 10, 100,
000,  10,000 and 100,000 parasites. The DNA in each of
hese  samples was then extracted using the Wizard kit
Promega, Madison, WI)  according to the manufacturer’s
nstructions.
TaqMan (Applied Biosystems) assays were performed
sing the ABI PRISM 7500 system (Applied Biosystems) and
rimers  based on leishmanial minicircle kinetoplast DNA
Applied  Biosystems) with threshold cycle numbers (Ct)
hat  were determined using the RQ Study software package
Applied Biosystems). Reactions were performed in tripli-
ate,  and the mean Ct values were used in the ﬁnal analysis.
he  following protocol was programmed into the thermo-
ycler: 2 min  at 50 ◦C, 10 min  at 95 ◦C and 45 cycles of 15 s
t  95 ◦C and 1 min  at 60 ◦C.
The  forward and reverse primers – 5′-GGT TAG CCG
TG GTG GTC TT-3′ and 5′-GCT ATA TCA TAT GTC CAA
CA  CTT ACCT-3′, respectively – were used with TaqMan
Applied Biosystems) and an internal probe (5-ACC ACC
AA  GGT CAA CCC-3) (Rolão et al., 2004). For each assay, 20-
l  reaction mixture contained 2 l of DNA sample, 10 l of
aqMan Universal PCR master mix  (Applied Biosystems),
 l of a 200-nM solution of each unlabeled primer, and
aqMan MGB  probe (FAMTM dye-labelled) mix  (Applied
iosystems). The standard curve and negative control sam-
les  were also submitted to these procedures. The point at
hich  ﬂuorescence exceeded the threshold limit indicated
he  Ct value.
.5.  Leishmania antigens
The  antigens used for the Western Blot analyses and
n  vitro stimulation of peripheral blood mononuclear cells
o  assess the production of cytokines were prepared by cul-
uring  L. infantum promastigotes (MHOM/BR/1967/BH46)
n NNN-LIT for 7 days at 23 ◦C (Andrade et al., 1999).
.6. Assessment of cytokines
Peripheral  blood mononuclear cells were harvested in a
istopaque gradient (Sigma Chemical Co., USA) in sterile,
onical bottom, polystyrene tubes (Falcon-Corning, USA).
fter  centrifugation at 400 × g for 45 min  at 18 ◦C, the pellet
f  mononuclear cells was recovered. The cells were washed
hree  times with RPMI-1640 medium and centrifuged at
00  × g and 4 ◦C for 10 min. The cell concentration was
djusted to 1.5 × 106 cells/mL in RPMI-1640 medium sup-
lemented with 5% fetal bovine serum, 2-mercaptoethanol,
EPES, and 10 IU of penicillin/streptomycin/mL. Onesitology 181 (2011) 83– 90 85
milliliter of cell suspension was  added to two  wells of a
24-well  polystyrene plate (Coast, USA). One well was ﬁlled
with  50 L of L. infantum whole antigen extract (1 mg/mL),
while another was reserved for the negative control (with-
out  Leishmania antigens). This 24-well plate was incubated
for  72 h at 37 ◦C in an atmosphere containing 95% rela-
tive humidity and 5% CO2. The supernatant was  collected
and stored at −70 ◦C until assay. The levels of IFN-, IL-4
and IL-10 cytokines were evaluated with double sandwich
Enzyme Linked Immunosorbent Assay (ELISA) using anti-
bodies  and reagents purchased from R&D Systems.
2.7. Western blot analysis
SDS-polyacrylamide gel electrophoresis was performed
in  a vertical gel apparatus (Bio-Rad). The antigen was boiled
for  5 min  in sample buffer and immediately subjected to
electrophoresis in a 10% polyacrylamide gel containing
0.1% SDS as described by Laemmli (1970). Three hundred
micrograms of protein was  used for electrophoresis. The
gels  were run at 15 mA  for the stacking gel and 30 mA for
the  resolution gel until the bromophenol blue dye migrated
to  1 cm from the bottom of the gel in Tris–glycine–SDS
buffer (pH 8.3).
Western  blotting (WB) was carried out as described
(Cuquerella et al., 1991). Proteins were electroblotted
overnight onto nitrocellulose membranes (0.45-m pore
size,  Hybond® GE Healthcare) and the strips probed with
dog  sera (1:100 in 1% bovine serum albumin–TBS) for 2 h.
Secondary antibody was anti-dog IgG (1:500) horseradish
peroxidase-labelled (Sigma) and after incubation, the
membrane was washed three or four times with Tween
20–TBS and developed with the 3,3′-diaminobenzidine
plus 4-chloro-1-naphthol system (SIGMA) for 5 min. The
reaction  was  stopped with deionized water. Molecular
weight (MW)  markers (116, 97.4, 66, 45 and 29 kDa) were
purchased from GE Healthcare.
2.8.  Assessment of IgG levels
Plasma obtained from the blood samples collected for
the  cytokine evaluation was used for the IgG levels deter-
mination through ELISA performed exactly as described by
McLaren  et al. (1980).
2.9.  Statistical analyses
Considering  the nature of the variables, non-parametric
tests with a signiﬁcance level of 0.05 were used. The
Wilcoxon test was employed for the parasite load analysis.
The  Kruskal–Wallis non-parametric test was used for the
cytokine analysis within the different groups, and ANOVA
was  used for the evaluation of serum IgG levels.
3. Results
3.1. Clinical evaluationThe  animals monitored here started as asymptomatic
(n = 1), oligosymptomatic (n = 5) and symptomatic (n = 8) in
agreement  to Mancianti et al. (1998). The most prevalent
86 H.M. Andrade et al. / Veterinary Parasitology 181 (2011) 83– 90
d 24 mo
1,  2 and 3, respectively, showing an increase tendency,
mainly in group 2 whose animals were treated with the
highest  miltefosin dosage.
Table 1
Leishmania detection in dog bone marrow before and after miltefosine




3 months 6  months 24  monthsFig. 1. Clinical evaluation before an
clinical signs were dermatitis (61.5%), onychogryphosis
(53.8%), alopecia (46.1%), lymphadenopathy (30.7%) and
conjunctivitis (23.5%). After treatment and during the 24
months  of follow-up, there was progressive improvement
and complete clinical recovery in 50% (7/14) of the treated
animals. For the others, 21.4% (3/14) presented two  or three
symptoms of CVL, 14.3% (2/14) were symptomatic and two
(14.3%)  of the dogs died after 22 and 23 months of acute
renal failure and cachexia, respectively (Fig. 1).
3.2. Biochemical evaluation
Reference  values were used for all laboratory tests as
reported by Kaneko et al. (1997). The hepatic function
was estimated through the total protein, globulin, albu-
min,  ALAT, ASAT and bilirubin levels. The most frequent
ﬁnding was an increase in the total protein and globulin
levels. Albumin levels remained within the normal limits.
Direct  bilirubin increased in group 3 (animals treated with
100  mg  miltefosine for 45 days) after treatment.
Regarding the renal function, most animals presented
an increase in the urea concentration before treatment, and
the  level did not return to normal after 24 months of follow-
up.  The full blooded values ranged from 35 to 55 mg  per
dL.
3.3.  Parasitological evaluation
Parasites were identiﬁed in bone marrow samples
through microscopic examination of smears after Giemsa
staining, cultures, and qPCR. All of the samples were ana-
lyzed  before and 3, 6 and 24 months after treatment. At
the  beginning of the study, amastigotes were identiﬁed in
bone  marrow slides from all of the animals, and the para-
site  was isolated in NNN-LIT culture from 75% of subjects.
There was a decrease in the number of positive smears at
3  months post-treatment (14.2%), which was lower at 6
months  (7.1%), and returning a 14.2% after two years. There
was  also a gradual and constant decrease in the number of
positive  cultures at the end of the monitoring period. How-
ever,  the detection of the parasite DNA by PCR remained
positive. These data are listed in Table 1.nths of follow-up after treatment.
It was not possible to assess the parasite loads in the
bone marrow smears in 5 of the 14 animals (35.7%). Two
progression patterns were observed. One group presented
a  signiﬁcant reduction in parasite load (p = 0.0277) after 3
months  of treatment, which included 66% of the animals
studied. In the second pattern, the animals showed a pro-
gressive  increase in parasite load after treatment (Fig. 2).
These  patterns have not any relationship with treatment
schedule, and thus, we are presenting the results accord-
ing  to these patterns, and not according to the treatment
group. In general, all of the animals presented a signiﬁcant
increase in parasite load 6 months after treatment relative
to  the ﬁrst pattern (p = 0.04664).
Also,  qPCR was  used to assess the parasite load in the
spleen 24 months after treatment. The reaction was posi-
tive  in 13/14 animals and ranged from 3250 to 66,493. 920
parasites/200 ng DNA (data not shown).
3.4. Cytokines production
IFN-  was produced in all of the groups, and the levels of
this  cytokine showed a tendency to increase during follow
up  treatment (Fig. 3) and to decrease at the end of follow up
in  all of the groups (data not shown), regardless the miltefo-
sine  dose. There was no signiﬁcant difference between the
different  time intervals analyzed for each group (p > 0.05),
however the p values were 0.68, 0.06 and 0.21 to the groups(%) (%) (%)
Smear 100 14.2 7.1 14.2
Culture 75 65 53.8 30.7
qPCR 100 100 100 100




















Fig. 4. IL-4 levels in the supernatant obtained from mononuclear cells
of dogs naturally infected with L. infantum, treated with miltefosine, and
stimulated with L. infantum antigens. Numbers 1–3 refer to the treatment
groups. BT, before treatment. The follow-up periods are shown at 180 and
300  days. O.D., optical density at 450 nm.  The vertical line represents the
standard deviation.
Fig. 5. IL-10 levels in the supernatant obtained from mononuclear cellsig. 2. L. infantum loads determined by real-time PCR in bone marrow.
oad ranges are expressed as parasite DNA/20 ng on a log scale.
Contrary to the effect on the levels of IFN-, the IL-4
Fig. 4) and IL-10 (Fig. 5) levels tended to decrease 180
ays after treatment, however, 300 days after treatment
L-4 remains low while IL-10 increases. The IL-4 decrease
as signiﬁcant (p < 0.05) in groups 1 and 3. However, the
ifferences in IL-10 levels during the time intervals the p
alues  for the groups were 0.15, 0.17 and 0.09, respectively.
.5. Humoral response
Regardless  of drug dose and therapeutic schedule of
reatment, the serum antibodies from the animals identi-
ed  a number of antigens with molecular weights ranging
rom  116 kDa to less than 29 kDa. Furthermore, qualitative
nd quantitative differences in the antigen proﬁles were
ig. 3. IFN- levels in the culture supernatant obtained from mononuclear
ells of dogs naturally infected with L. infantum, treated with miltefosine,
nd stimulated with L. infantum antigens. Numbers 1–3 refer to treatment
roups. BT, before treatment. The follow-up periods are shown at 180 and
00  days. O.D., optical density at 450 nm. The vertical line represents the
tandard deviation.
of dogs naturally infected with L. infantum, treated with miltefosine, and
stimulated with L. infantum antigens. Numbers 1–3 refer to the treatment
groups. BT, before treatment. The follow-up periods are shown at 180 and
300  days. O.D., optical density at 450 nm.  The vertical line represents the
standard deviation.
observed 60 days after treatment. In general, few antigens
were identiﬁed during this period. Furthermore, 300 days
after  treatment, other antigens were developed, particu-
larly those of 116, 97, 66 and 46 kDa molecular weight
(Fig. 6).
Antigen-speciﬁc Leishmania IgGs were detected in
higher levels before treatment and 300 days after follow
up  in all three groups. The average levels after 180 days
of  treatment, were signiﬁcantly different (p < 0.05) (Fig. 7).
The  IgG levels observed in the other two  groups presented
the  same proﬁle as that discussed for group 1 (data not
shown).
4.  Discussion
In the present study, miltefosine was  employed for
the  ﬁrst time in Brazil to treat dogs naturally infected
by L. infantum. Signiﬁcant clinical improvement that pro-
gressed  to full recovery was observed in most animals. The
main  side effect observed was transient, self-limited, and
88 H.M. Andrade et al. / Veterinary ParaFig. 6. Western blot proﬁle. Line 1 = negative control, line 2 = before treat-
ment (BT), lines 3 and 4, 60 and 300 days after treatment, respectively.
reversible vomiting, similar to that described by Woerly
et  al. (2009).The  anti-Leishmania activity of phospholipid analogues
has been demonstrated previously (Croft et al., 2003). In
other  countries, most of the clinical trials based on the
therapeutic efﬁcacy of different active compounds on dogs
Fig. 7. Levels of immunoglobulin G anti-Leishmania antigens in the
plasma of dogs treated with miltefosine (group 1). BT, before treatment.
O.D., optical density at 492 nm.  The vertical line represents the standard
deviation.sitology 181 (2011) 83– 90
naturally infected with L. infantum presented good clini-
cal  improvement and, in some cases, the total remission of
clinical  symptoms (Valladares et al., 2001; Pasa et al., 2005;
Oliva  et al., 2006; Ikeda-García et al., 2007), especially when
miltefosine was used alone or in combination with other
drugs  (Manna et al., 2008a,b,c; Mateo et al., 2009; Woerly
et  al., 2009).
The  main biochemical change observed was  an increase
in  the globulin level, which has been thoroughly described
in  the literature as the most common clinical and labora-
tory  ﬁnding for CVL. The parasites presence in the spleen
promotes an intense polyclonal activation of B cells and a
large  increase in the antibodies production, which reﬂects
the  increase in the globulin level (Amusategui et al., 2003).
Although other studies reporting absence of parasite in
bone  marrow of miltefosine-treated dogs during follow up
(Miró  et al., 2009), here was registered only a signiﬁcant
reduction in parasite load 3 months after treatment. The
presence of Leishmania DNA in tissue samples is indicative
of  the presence of the intact parasite because the nuclear
DNA and kDNA are rapidly degraded after amastigote death
(Disch  et al., 2004; Prina et al., 2007). Therefore, the use
of  miltefosine did not result in parasitological clearance of
CVL,  and it caused a progressive increase in the parasite
load, especially after 6 months. This result has also been
observed by Manna et al. (2008a). It is important to high-
light  that these discrepancies between the results of qPCR
could  be reasonably ascribed to the different sensitivity of
the  chosen target. It has been shown by Ovalle et al. (2007)
that  the minicircle kDNA target used here and in Manna
et  al. (2008a) is more sensitive than the ribosomal DNA
target used by Miró et al. (2009). Thus, we suggest that
qPCR  using kDNA target indicates that early intervention
is needed once recurrence is observed, which will thereby
increase the chances for canine recovery and reduce vector
contamination.
The  proﬁle of the main cytokines involved in the VL
healing process was investigated because the success of
any  kind of treatment requires a good understanding of the
speciﬁc  immunological responses to Leishmania infection.
Similar  to other groups, we also observed, increased lev-
els  of IFN- and a decrease in IL-4 during follow up (Manna
et  al., 2008b). Similarly, Chamizo et al. (2005) observed that
the  expression of IFN- was lower before therapy than dur-
ing  treatment and IL-4 was active during the initial defence
against Leishmaniasis. In the present study, when the para-
site  load in bone marrow aspirates were decreased 90 days
after  treatment, the IFN- levels were increased.
In addition, mixed production of the IFN- and IL-4
cytokines, with Th2 dominance, was  observed at the time
of  diagnosis. During treatment with miltefosine, the Th1
response became predominant. In fact, IFN- expression
levels increased. These ﬁndings demonstrate a relation-
ship between the detection of IFN- and the control of
Leishmaniasis and suggest that IFN- may  represent a good
marker  for predicting relapse of the disease in infected
dogs and for determining the effectiveness of treatment.
Furthermore, the results also demonstrated that IL-4 rep-
resents  a marker for the active disease. This fact suggests
that, as observed by other authors, clearance of parasites
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s regulated by mechanisms that govern the production of
amma  interferon (Kaye et al., 2004; Wilson et al., 2005).
The  improvement of symptoms was, at least in part, the
esult  of the cytokine proﬁle that developed in the immune
nimals during treatment. An increase in IL-10 levels at
he  end of follow up was observed. IL-10 might regulate
he possible damage caused by the exacerbated effects of
FN- as  a consequence of the dominant Th1-like response.
dditionally, IL-10 could act as a regulatory factor that
aintains the balance between the Th1- and Th2-type cells
Kemp  et al., 1999).
Apparently, the Th1 response could be prevalent at the
nd  of follow up treatment. In fact, IFN- expression levels
howed a tendency to increase. However, immunological
nd parasitological relapses, a signiﬁcant reduction in IFN-
,  and an increase in IL-4 expression were observed in some
ogs  after 24 months.
The  humoral immune response occurs during the active
hase  of infection, with the appearance of high titers
f  antibodies that decreased a few months after treat-
ent, which represents a temporary response. This fact has
ade  the assessment of antibody proﬁles a useful tool for
he  follow-up of dogs after therapy and for deﬁning the
rognostic period during which the veterinarians should
bserve the animals.
Similarly,  the antigenic proﬁles revealed by western blot
ere  correlated with the serological data. More complex
ntigenic proﬁles were identiﬁed before and 300 days after
reatment, which may  reﬂect increased antigen stimula-
ion  during these periods that lead to an increase in the
oncentration of IgG in these time points as shown by the
mmunoenzymatic reaction.
.  Conclusion
In  conclusion, miltefosine promotes clinical improve-
ent in animals with low parasite loads and low degrees
f  stimulation of humoral immunity. It also caused an
ncrease in IFN- production. However, the improve-
ent in the clinical symptoms was not accompanied by
arasitological clearance, suggesting that treatment with
iltefosine is not recommended, especially in endemic
reas like Brazil, where children are the major victims and
ogs  are involved in the maintenance of the parasite cycle.
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